Passage Bio Presents Preclinical And Interim Clinical Data As Part Of An Oral Presentation At ESGCT 31St Annual Congress Being Held October 22-25, 2024, In Rome, Italy
Passage Bio Presents Preclinical And Interim Clinical Data As Part Of An Oral Presentation At ESGCT 31St Annual Congress Being Held October 22-25, 2024, In Rome, Italy
Passage Bio將在2024年10月22日至25日在意大利羅馬舉行的ESGCt第31屆年度大會上，作爲口頭報告的一部分，展示臨床前和中期臨床數據。
Preclinical data demonstrated that an AAV1 vector achieved superior human progranulin levels in the CSF as compared to AAV5 and AAVhu68 (an AAV9 variant).
臨床前數據表明，AAV1載體在CSF中實現了優越的人類progranulin水平，與AAV5和AAVhu68（AAV9變體）相比。
Nonclinical data showed PBFT02 improved lysosomal histopathology and reduced neuroinflammation in Grn knockout mice, and achieved widespread vector distribution throughout the nervous system in non-human primates
非臨床數據顯示PBFT02改善了Grn基因敲除小鼠的溶酶體組織學病變並減少了神經炎症，在非人靈長類動物的神經系統中實現了廣泛的載體分佈。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間